CNS relapses tend to occur early, with the median time from DLBCL diagnosis to CNS relapse reported in most studies at between 6 and 8 months. Therefore, there is rationale to deliver CNS prophylaxis as early as possible during treatment.
What is CNS prophylaxis?
CNS prophylaxis is given when the cancer is diagnosed because standard chemotherapy cannot get into the CNS and kill cancer cells that may be hiding in there. It is used to lessen the chance cancer will come back in the CNS after the first treatment.
How do you treat CNS relapse lymphoma?
Chimeric antigen receptor T-cell therapy, which has recently been approved for the treatment of relapsed/refractory systemic DLBCL, was shown to be effective in a patient with secondary CNS lymphoma. Clinical trials with chimeric antigen receptor T cells in patients with CNS lymphoma are in development.
How do you cope with lymphoma diagnosis?
Treatment
- Active surveillance. Some forms of lymphoma are very slow growing.
- Chemotherapy. Chemotherapy uses drugs to destroy fast-growing cells, such as cancer cells.
- Radiation therapy.
- Bone marrow transplant.
- Other treatments.
What is CNS IPI?
The CNS-IPI is a robust, highly reproducible tool that can be used to estimate the risk of CNS relapse/progression in patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.
What is a CNS lymphoma?
Primary central nervous system (CNS) lymphoma is a disease in which malignant (cancer) cells form in the lymph tissue of the brain and/or spinal cord. Having a weakened immune system may increase the risk of developing primary CNS lymphoma.
Is CNS lymphoma genetic?
Genetic studies demonstrate that CNS lymphomas exhibit a distinct gene expression profile compared with nodal lymphomas of the same histologic type. Emerging data also indicate that CNS lymphomas are derived from a distinct cell of origin and exhibit a unique immunophenotype.
Can you cure CNS lymphoma?
Primary central nervous system (CNS) lymphoma is a rare and aggressive CNS neoplasm with a high morbidity and often fatal outcome. However, many patients may be cured. Diagnostic pitfalls in this uncommon tumor can lead to a missed or delayed diagnosis, causing mismanagement and treatment delays.
What is the CNS involvement in diffuse large B-cell lymphoma (DLBCL)?
Central nervous system (CNS) involvement with diffuse large B-cell lymphoma (DLBCL) is a relatively uncommon manifestation; with most cases of CNS involvement occuring during relapse after primary therapy. CNS dissemination typically occurs early in the disease course and is most likely present subc …
What does co-expression of Myc and Bcl2 in diffuse large B-cell lymphoma indicate?
Immunohistochemically detectable co-expression of MYC and BCL2 in the absence of translocations also portends an increased risk of relapse within the central nervous system, particularly in the setting of the activated B-cell-like subtype of diffuse large B-cell lymphoma.
Is universal application of CNS prophylaxis justified in DLBCL?
Based on a CNS relapse rate of 5% in DLBCL and weighing the benefits against the toxicities, universal application of CNS prophylaxis is not justified. The introduction of rituximab has significantly reduced the incidence of CNS relapse in DLBCL.
Does prophylactic intrathecal chemotherapy with methotrexate improve survival in DLBCL?
Prophylactic intrathecal chemotherapy (ITC) with agents such as Methotrexate (MTX) can mitigate the risk of recurrence and improve survival. We report a single-institution, retrospective analysis of the effect of ITC administration on outcomes in patients with DLBCL, based on CNS-IPI risk stratification.
